Krilogy Financial LLC Buys 11,664 Shares of Boston Scientific Corporation $BSX

Krilogy Financial LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 45.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,283 shares of the medical equipment provider’s stock after buying an additional 11,664 shares during the quarter. Krilogy Financial LLC’s holdings in Boston Scientific were worth $1,627,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Boston Scientific in the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific in the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $803,357,000. Janus Henderson Group PLC raised its stake in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares during the period. Finally, Amundi raised its stake in shares of Boston Scientific by 1.2% during the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock valued at $610,158,000 after purchasing an additional 173,208 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent research reports. UBS Group reduced their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. BTIG Research lowered their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a report on Wednesday, September 9th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $54.00 price target (down from $60.00) on shares of Boston Scientific in a research note on Saturday, October 3rd. Finally, Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $68.23.

Boston Scientific Trading Up 2.7%

Shares of BSX opened at $44.17 on Friday. The company has a market capitalization of $64.02 billion, a P/E ratio of 17.88, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a one year low of $41.38 and a one year high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a 50-day moving average price of $46.16 and a 200 day moving average price of $49.80.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Insider Activity

In related news, Director Edward Ludwig purchased 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Habiger purchased 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.